首页> Cancer cell international> Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines.

Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines.

导出 OA

翻译打印收藏纠错

第一作者： L-M,Sklarz

第一单位： Department of Medicine, Clinic III - Hematology/Oncology/Palliative Care, Rostock University Medical Center, Rostock, Germany.

作者： L-M,Sklarz ^[1] ; Y S,Gladbach ^[2] ; M,Ernst ^[3] ; M,Hamed ^[4] ; C,Roolf ^[1] ; S,Sender ^[1] ; J,Beck ^[5] ; E,Schütz ^[5] ; S,Fischer ^[4] ; S,Struckmann ^[4] ; C,Junghanss ^[1] ; G,Fuellen ^[1] ; H,Murua Escobar ^[1]

作者单位： Department of Medicine, Clinic III - Hematology/Oncology/Palliative Care, Rostock University Medical Center, Rostock, Germany. ^[1] Institute for Biostatistics and Informatics in Medicine and Ageing Research (IBIMA), Rostock University Medical Center, Rostock, Germany.;Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.;Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany. ^[2] Institute for Biostatistics and Informatics in Medicine and Ageing Research (IBIMA), Rostock University Medical Center, Rostock, Germany.;Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. ^[3] Institute for Biostatistics and Informatics in Medicine and Ageing Research (IBIMA), Rostock University Medical Center, Rostock, Germany. ^[4] Chronix Biomedical GmbH, Göttingen, Germany. ^[5]

关键词 Acute lymphoblastic leukaemia Cytarabine Cytostatics Dexamethasone Drug combinations Idelalisib PIK3-inhibition

DOI 10.1186/s12935-020-01431-4

PMID 32817744

发布时间 2023-11-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交